查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668140

天花治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療類型、產品類型、最終用戶、地區和競爭細分，2020-2030 年

Smallpox Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Product Type, By End user, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球天花治療市場價值為 7,456 萬美元，預計到 2030 年將達到 7,799 萬美元，預測期內複合年成長率為 3.71%。近年來，全球天花治療市場取得了重大發展，標誌著對抗這場毀滅性病毒性疾病的鬥爭進入了充滿希望的時代。天花曾是全球健康的威脅，由於大規模的疫苗接種運動，它於 1980 年被宣布根除。然而，對天花可能再次成為生物恐怖主義威脅以及相關痘病毒的出現的擔憂，重新點燃了對有效治療的需求。根據 2024 年 10 月 22 日更新的 CDC資料，天花已被根除，自 1977 年以來沒有報告病例。雖然天花不再自然發生，但天花病毒被用於生物攻擊的潛在風險仍然存在。儘管可能性很低，公共衛生當局仍繼續實施應對措施，以應對天花作為生物武器可能帶來的威脅。

市場概況
預測期 2026-2030
2024 年市場規模 7,456 萬美元
2030 年市場規模 7,799 萬美元
2025-2030 年複合年成長率 3.71％
成長最快的領域 抗病毒藥物
最大的市場 北美洲

天花是由天花病毒引起的，是一種傳染性極強且常常致命的疾病，困擾了人類數百年。它造成了無數死亡和普遍的苦難。幸運的是，由於疫苗接種計劃的成功，世界衛生組織 (WHO) 於 1980 年宣布天花已被根除。全球天花治療市場已針對這些問題發生了變化。研究和開發工作已成功研發出抗病毒藥物和疫苗，為天花疫情的爆發帶來希望。人們越來越意識到天花可能被用作生物恐怖主義武器，這刺激了人們對治療方法的研究和開發的投資。各國政府和國際組織正積極努力確保做好準備。分子生物學和基因組學的進步使得能夠抑制天花病毒複製的針對性抗病毒藥物的開發成為可能，從而提供了更有效的治療選擇。國際合作在匯集資源和知識應對潛在天花疫情方面發揮了至關重要的作用。世界衛生組織和疾病管制與預防中心（CDC）等組織處於這些努力的最前線。

主要市場促進因素

日益嚴重的生物恐怖主義威脅推動全球天花治療市場的發展

主要市場挑戰

開發成本高

主要市場趨勢

技術進步推動全球天花治療市場

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球天花治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（抗病毒藥物、疫苗接種、支持性治療）
    • 依產品類型（疫苗、抗病毒藥物）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美天花治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第7章：歐洲天花治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太天花治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲天花治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲天花治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Bavarian Nordic A/S
  • Chimerix, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Novartis AG
  • Johnson & Johnson
  • SIGA Technologies, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Bharat Biotech International Ltd.

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 18842

Global Smallpox Treatment Market was valued at USD 74.56 Million in 2024 and is expected to reach USD 77.99 Million by 2030 with a CAGR of 3.71% during the forecast period. The global smallpox treatment market has witnessed significant developments in recent years, marking a promising era in the battle against this devastating viral disease. Smallpox, once a global health threat, was declared eradicated in 1980, thanks to widespread vaccination campaigns. However, concerns about the potential re-emergence of smallpox as a bioterrorism threat and the emergence of related poxviruses have reignited the need for effective treatments. As per CDC data updated on October 22, 2024, smallpox has been eradicated, with no reported cases since 1977. The disease, characterized by rashes, was transmitted through coughing and sneezing. While smallpox no longer occurs naturally, there remains a potential risk of the variola virus being used in a biological attack. Although the likelihood is low, public health authorities continue to implement preparedness measures to address the possible threat of smallpox as a bioweapon.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 74.56 Million
Market Size 2030USD 77.99 Million
CAGR 2025-20303.71%
Fastest Growing SegmentAntiviral Drugs
Largest MarketNorth America

Smallpox, caused by the variola virus, is a highly contagious and often fatal disease that plagued humanity for centuries. It was responsible for countless deaths and widespread suffering. Fortunately, due to the success of vaccination programs, the World Health Organization (WHO) declared smallpox eradicated in 1980. However, the virus still exists in two known laboratory stockpiles, raising concerns about potential misuse. The global smallpox treatment market has evolved in response to these concerns. Research and development efforts have led to the creation of antiviral drugs and vaccines that hold promise in the event of a smallpox outbreak. The increased awareness of the potential use of smallpox as a bioterrorism agent has spurred investments in research and development of treatments. Governments and international organizations are actively working to ensure preparedness. Advances in molecular biology and genomics have enabled the development of targeted antiviral drugs that can inhibit the replication of the variola virus, offering more effective treatment options. International collaboration has played a crucial role in pooling resources and knowledge to tackle potential smallpox outbreaks. Organizations like the WHO and the Centers for Disease Control and Prevention (CDC) are at the forefront of these efforts.

Key Market Drivers

Increasing Bioterrorism Threat is Driving the Global Smallpox Treatment Market

The growing concern over bioterrorism has significantly fueled the expansion of the global smallpox treatment market. Smallpox, once eradicated, remains a potential biological weapon due to its high transmissibility and fatality rate. Governments worldwide, along with international health organizations, are investing heavily in research, development, and stockpiling of smallpox vaccines and antiviral treatments as a precautionary measure. The fear that smallpox could be weaponized in a bioterror attack has led to strategic collaborations between governments, pharmaceutical companies, and research institutions, accelerating the market's growth.

Advancements in biotechnology and genetic engineering have enabled scientists to develop next-generation vaccines and antiviral treatments, enhancing preparedness against potential smallpox outbreaks. Research is focused on developing safer and more effective vaccines with fewer side effects, making them viable for mass immunization in case of emergency. Antiviral drugs targeting the variola virus are undergoing clinical trials to expand treatment options beyond vaccines. National security agencies have also played a vital role in bolstering smallpox preparedness efforts. Countries such as the United States have allocated substantial budgets to smallpox-related biodefense initiatives, supporting the procurement of medical countermeasures. Governments are proactively stockpiling vaccines, ensuring sufficient supplies in the event of an attack. On

Key Market Challenges

High Development Costs

The development of smallpox treatment products, including vaccines and antiviral drugs, requires substantial financial investment due to the complexity of research, clinical trials, and regulatory compliance. Smallpox, as a Category A bioterrorism agent, necessitates stringent biosafety measures, which further drive up costs. Developing vaccines and antiviral drugs involves extensive preclinical and clinical trials to ensure efficacy and safety, requiring significant funding from pharmaceutical companies, government agencies, and global health organizations.

One of the major financial burdens is the long research and development (R&D) timeline. Since smallpox is eradicated, traditional large-scale human clinical trials are not feasible, necessitating alternative pathways such as animal models and immune response studies, which increase expenses. Stringent regulatory requirements from agencies like the FDA, EMA, and WHO mandate extensive documentation and safety assessments before approval, prolonging the time-to-market and adding to costs.

Manufacturing smallpox treatments requires high-containment biosafety laboratories, further inflating operational expenses. Pharmaceutical companies must invest in specialized facilities and bioprocessing technologies to prevent viral exposure and contamination. Given the low commercial demand for smallpox treatments-since the disease is not naturally occurring-companies find it difficult to justify continued investment in research, making government and defense contracts the primary sources of funding. Ultimately, the high cost of development limits market entry for new players, leading to reduced competition and slower innovation. Without continued financial incentives or government-backed initiatives, pharmaceutical companies may deprioritize smallpox treatment development, potentially weakening global preparedness for future outbreaks.

Key Market Trends

Technological Advancements Driving the Global Smallpox Treatment Market

Technological advancements continue to revolutionize the healthcare sector, and their impact on the Global Smallpox Treatment Market has been particularly significant. With growing concerns over the potential re-emergence of smallpox as a bioterrorism threat, the development of innovative vaccines, antiviral treatments, and diagnostic tools has gained momentum. These advancements have enhanced the preparedness of governments and healthcare organizations to respond swiftly in case of an outbreak. One of the key breakthroughs in smallpox treatment is the development of next-generation vaccines. Traditional smallpox vaccines, such as those based on live vaccinia virus, have been effective but are associated with certain safety risks. Modern vaccine technologies, including DNA vaccines, recombinant vaccines, and viral vector-based platforms, are being explored to provide enhanced immunity with fewer side effects. These new-generation vaccines offer better safety profiles and can be mass-produced quickly, making them crucial for emergency preparedness.

Alongside vaccine development, antiviral drug research has also progressed significantly. The introduction of new smallpox antiviral agents, such as tecovirimat and brincidofovir, has expanded treatment options. These drugs work by targeting the replication mechanisms of the Variola virus, reducing disease severity and improving patient outcomes. Continued research into broad-spectrum antiviral drugs is further strengthening treatment options.

The field of diagnostics has also benefited from technological advancements. Polymerase chain reaction (PCR)-based assays and next-generation sequencing (NGS) have enabled rapid and accurate detection of smallpox infections. These tools are vital for early diagnosis and containment strategies. Advancements in biosensors and point-of-care diagnostic devices allow for quicker screening in potential outbreak scenarios. Biotechnology has played a crucial role in smallpox research, leading to the development of monoclonal antibodies and targeted therapies capable of neutralizing the virus. As technological innovations continue to evolve, they will remain central to strengthening the global response against smallpox threats.

Key Market Players

  • Bavarian Nordic A/S
  • Chimerix, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Novartis AG
  • Johnson & Johnson
  • SIGA Technologies, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Bharat Biotech International Ltd

Report Scope:

In this report, the Global Smallpox Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Smallpox Treatment Market, By Treatment Type:

  • Antiviral Drugs
  • Vaccination
  • Supportive Care

Smallpox Treatment Market, By Product Type:

  • Vaccines
  • Antiviral Drugs

Smallpox Treatment Market, By End user:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Smallpox Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Smallpox Treatment Market.

Available Customizations:

Global Smallpox Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Smallpox Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Antiviral Drugs, Vaccination, Supportive Care)
    • 5.2.2. By Product Type (Vaccines, Antiviral Drugs)
    • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others),
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Smallpox Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Product Type
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Smallpox Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Smallpox Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Smallpox Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By End user

7. Europe Smallpox Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Product Type
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Smallpox Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By End user
    • 7.3.2. United Kingdom Smallpox Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By End user
    • 7.3.3. Italy Smallpox Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By End user
    • 7.3.4. France Smallpox Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Smallpox Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By End user

8. Asia-Pacific Smallpox Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Product Type
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Smallpox Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By End user
    • 8.3.2. India Smallpox Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Smallpox Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Smallpox Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Smallpox Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By End user

9. South America Smallpox Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Product Type
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Smallpox Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By End user
    • 9.3.2. Argentina Smallpox Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By End user
    • 9.3.3. Colombia Smallpox Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By End user

10. Middle East and Africa Smallpox Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Product Type
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Smallpox Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By End user
    • 10.3.2. Saudi Arabia Smallpox Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By End user
    • 10.3.3. UAE Smallpox Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Bavarian Nordic A/S
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Chimerix, Inc.
  • 14.3. Pfizer Inc.
  • 14.4. Sanofi SA
  • 14.5. GlaxoSmithKline plc
  • 14.6. Novartis AG
  • 14.7. Johnson & Johnson
  • 14.8. SIGA Technologies, Inc.
  • 14.9. BioCryst Pharmaceuticals, Inc.
  • 14.10. Bharat Biotech International Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer